NBD-556

NBD-556

Catalog Number:
L002368780APE
Mfr. No.:
APE-A3649
Price:
$257
  • Size:
    Quantity:
    Add to Cart:
      • Overview
        • Please contact us at for specific academic pricing.

          Background

          IC50: NBD-556 inhibited cell–cell fusion between H9/HIV-1IIIB and MT-2 (IC50 ~3 μM)
          The entry of HIV-1 into host cells is mediated by the binding of the surface subunit gp120 to the host cell receptor CD4. NBD-556 is a novel class of human immunodeficiency virus type 1 (HIV-1) entry inhibitor that block the gp120–CD4 interaction with drug-like properties.
          In vitro: A systematic study showed that NBD-556 and NBD-557 target viral entry by inhibiting the binding of HIV-1 envelope glycoprotein gp120 to the cellular receptor CD4 but did not inhibit reverse transcriptase, protease, or integrase, demonstrating that they do not target the later stages of the HIV-1 life cycle to inhibit HIV-1 infection. NBD-556 and NBD-557 were also active against HIV-1 laboratory-adapted strains including an AZT-resistant strain and HIV-1 primary isolates, showing that these compounds can potentially be further modified to become potent HIV-1 entry inhibitors [1].
          In vivo: No animal in-vivo data available currently.
          Clinical trial: No clinical data are available.

      • Properties
        • Alternative Name
          NBD 556;NBD556; N'-(4-chlorophenyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide
          CAS Number
          333353-44-9
          Molecular Formula
          C17H24ClN3O2
          Molecular Weight
          337.84
          Purity
          98.00%
          Solubility
          Soluble in DMSO
          Storage
          Store at -20°C

          * For Research Use Only

    Note: If you don't receive our verification email, do the following:

    Copyright © Amerigo Scientific. All rights reserved.